Trial Profile
A single dose, randomised, 2-period, 2-sequence, crossover, comparative bioavailability study between 4 x 60 mg R107 tablets administered orally and 0.5mg/kg ketamine IV infusion over 40 minutes in healthy male and female participants under fasting conditions.
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Oct 2021
Price :
$35
*
At a glance
- Drugs Ketamine (Primary) ; Ketamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- 26 Oct 2021 Planned initiation date changed from 18 Jul 2018 to 1 Mar 2022.
- 13 Jul 2018 New trial record